{"id":"https://openalex.org/W4362481381","doi":"https://doi.org/10.1158/2159-8290.22531194.v1","title":"Supplementary Table S1 from The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma","display_name":"Supplementary Table S1 from The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma","publication_year":2023,"publication_date":"2023-04-03","ids":{"openalex":"https://openalex.org/W4362481381","doi":"https://doi.org/10.1158/2159-8290.22531194.v1"},"language":"en","primary_location":{"id":"doi:10.1158/2159-8290.22531194.v1","doi":"https://doi.org/10.1158/2159-8290.22531194.v1","is_oa":true,"landing_page_url":"https://doi.org/10.1158/2159-8290.22531194.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"supplementary-materials","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/2159-8290.22531194.v1","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5040149772","display_name":"Nicole R. Infarinato","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Nicole R. Infarinato","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103048363","display_name":"Jin H. Park","orcid":"https://orcid.org/0000-0001-7017-4979","observed_orcids":["https://orcid.org/0000-0001-7017-4979"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jin H. Park","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053226567","display_name":"Kateryna Krytska","orcid":"https://orcid.org/0009-0009-8402-8687","observed_orcids":["https://orcid.org/0009-0009-8402-8687"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kateryna Krytska","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019240347","display_name":"Hannah T. Ryles","orcid":"https://orcid.org/0000-0001-5126-9075","observed_orcids":["https://orcid.org/0000-0001-5126-9075"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hannah T. Ryles","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102864493","display_name":"Renata Sano","orcid":"https://orcid.org/0000-0001-9630-3388","observed_orcids":["https://orcid.org/0000-0001-9630-3388"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Renata Sano","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109498052","display_name":"Katherine M. Szigety","orcid":"https://orcid.org/0000-0001-9754-6381","observed_orcids":["https://orcid.org/0000-0001-9754-6381"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Katherine M. Szigety","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017202683","display_name":"Yimei Li","orcid":"https://orcid.org/0000-0001-9067-6992","observed_orcids":["https://orcid.org/0000-0001-9067-6992","https://orcid.org/0000-0002-7046-4316"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yimei Li","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023840148","display_name":"Helen Y. Zou","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Helen Y. Zou","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072732582","display_name":"Nathan V. Lee","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Nathan V. Lee","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004738391","display_name":"Tod Smeal","orcid":"https://orcid.org/0009-0000-0320-7451","observed_orcids":["https://orcid.org/0009-0000-0320-7451"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Tod Smeal","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073959537","display_name":"Mark A. Lemmon","orcid":"https://orcid.org/0000-0002-3379-5319","observed_orcids":["https://orcid.org/0000-0002-3379-5319"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mark A. Lemmon","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5030496565","display_name":"Ya\u00ebl P. Moss\u00e9","orcid":"https://orcid.org/0000-0002-3463-0399","observed_orcids":["https://orcid.org/0000-0002-3463-0399"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yael P. Moss\u00e9","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12226","display_name":"Neuroblastoma Research and Treatments","score":0.8476999998092651,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12226","display_name":"Neuroblastoma Research and Treatments","score":0.8476999998092651,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.13779999315738678,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11173","display_name":"Neurofibromatosis and Schwannoma Cases","score":0.0007999999797903001,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/crizotinib","display_name":"crizotinib","score":0.8790000081062317},{"id":"https://openalex.org/keywords/alk-inhibitors","display_name":"ALK inhibitors","score":0.8069999814033508},{"id":"https://openalex.org/keywords/ros1-inhibitors","display_name":"ROS1 inhibitors","score":0.8220000267028809},{"id":"https://openalex.org/keywords/crizotinib-resistance","display_name":"crizotinib resistance","score":0.8759999871253967},{"id":"https://openalex.org/keywords/alk-mutations","display_name":"ALK mutations","score":0.824999988079071},{"id":"https://openalex.org/keywords/neuroblastoma-cell-lines","display_name":"neuroblastoma cell lines","score":0.8650000095367432},{"id":"https://openalex.org/keywords/ic50","display_name":"IC50","score":0.8679999709129333}],"concepts":[{"id":"https://openalex.org/C2779422266","wikidata":"https://www.wikidata.org/wiki/Q5186964","display_name":"Crizotinib","level":4,"score":0.9974089860916138},{"id":"https://openalex.org/C2778347629","wikidata":"https://www.wikidata.org/wiki/Q4652380","display_name":"ALK inhibitor","level":5,"score":0.766048789024353},{"id":"https://openalex.org/C2775999482","wikidata":"https://www.wikidata.org/wiki/Q18031208","display_name":"ROS1","level":4,"score":0.6842365860939026},{"id":"https://openalex.org/C117643217","wikidata":"https://www.wikidata.org/wiki/Q17824987","display_name":"Anaplastic lymphoma kinase","level":4,"score":0.6362334489822388},{"id":"https://openalex.org/C2777752497","wikidata":"https://www.wikidata.org/wiki/Q286779","display_name":"IC50","level":3,"score":0.5443084836006165},{"id":"https://openalex.org/C2776715637","wikidata":"https://www.wikidata.org/wiki/Q938205","display_name":"Neuroblastoma","level":3,"score":0.4854765236377716},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.36248138546943665},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.3510218560695648},{"id":"https://openalex.org/C81885089","wikidata":"https://www.wikidata.org/wiki/Q189082","display_name":"Cell culture","level":2,"score":0.350819855928421},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.34657177329063416},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.31987136602401733},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.24579858779907227},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.18299445509910583},{"id":"https://openalex.org/C2781182431","wikidata":"https://www.wikidata.org/wiki/Q356033","display_name":"Adenocarcinoma","level":3,"score":0.12051966786384583},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.11327746510505676},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.080850750207901},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.07866218686103821},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.06788203120231628},{"id":"https://openalex.org/C2776232967","wikidata":"https://www.wikidata.org/wiki/Q6743514","display_name":"Malignant pleural effusion","level":3,"score":0.0}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1158/2159-8290.22531194.v1","doi":"https://doi.org/10.1158/2159-8290.22531194.v1","is_oa":true,"landing_page_url":"https://doi.org/10.1158/2159-8290.22531194.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"pmh:oai:figshare.com:article/22531194","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/journal_contribution/Supplementary_Table_S1_from_The_ALK_ROS1_Inhibitor_PF-06463922_Overcomes_Primary_Resistance_to_Crizotinib_in_ALK-Driven_Neuroblastoma/22531194","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1158/2159-8290.22531194.v1","doi":"https://doi.org/10.1158/2159-8290.22531194.v1","is_oa":true,"landing_page_url":"https://doi.org/10.1158/2159-8290.22531194.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9476000070571899,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2103600998","https://openalex.org/W2564097003","https://openalex.org/W4362512049","https://openalex.org/W2462717932","https://openalex.org/W2337713490","https://openalex.org/W2566076571","https://openalex.org/W1983845822","https://openalex.org/W2052546787","https://openalex.org/W2404235140","https://openalex.org/W2281758936"],"abstract_inverted_index":{"PF-06463922":[0,20,51],"is":[1],"potent":[2],"against":[3],"ALK-mutated":[4],"NB":[5,25],"cell":[6,26,36],"lines":[7,27],"in":[8,41,55],"vitro.":[9],"Mean":[10],"(n=3)":[11],"IC50":[12,43],"values":[13,44],"({plus":[14],"minus}":[15],"SD)":[16],"for":[17,23,50],"crizotinib":[18,46],"and":[19],"are":[21,52],"listed":[22,54],"10":[24],"harboring":[28],"the":[29,42,56],"indicated":[30],"ALK":[31],"aberrations,":[32],"plus":[33],"one":[34],"NSCLC":[35],"line":[37],"(NCI-H3122).":[38],"Fold":[39],"increases":[40],"with":[45],"over":[47],"those":[48],"measured":[49],"also":[53],"right-most":[57],"column.":[58]},"counts_by_year":[],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2023-04-05T00:00:00"}